Clinical Investigator Collaborative
AllerGen’s Clinical Investigator Collaborative (CIC) demonstrates how mutually beneficial partnerships can spark excellence in Canadian research and contribute to global pharmaceutical innovation.
The CIC is a globally unique clinical trial research unit and service provider for fast tracking early-stage drugs for proof-of-concept to use in Phase II trials.
The CIC predicts the effectiveness of potential new drugs for Allergic Asthma (AA-CIC), Allergic Rhinitis (AR-CIC) and Severe Asthma (SA-CIC) in a cost-effective, timely, and highly reliable clinical model.
CIC Fact Sheet
Success Stories profiles of CIC:
Additional AllerGen research contributions to drug development
Developing a Vaccine for Asthma and Allergies
Project: Vaccines for asthma & allergies – a bacterial immune-prophylactic and therapeutic approach
Principal investigator: Tobias Kollmann
Dr. Kollmann views vaccination as the most promising approach to preventing or treating allergy and asthma. The benefit, he says, lies in the fact that they address the problem at its source rather than temporarily alleviating symptoms.
Project: Environmental impact on the epithelial immune barrier in asthma
Principal investigator: Tony Bai
This team’s ground-breaking discoveries concerning damage and repair in asthma-affected airways are causing a major “buzz” within international research circles. Their discovery could lead to the development of a new type of medication that actually delays, changes, or interrupts the progression of asthma and COPD, instead of just managing the symptoms.
Project: Validation of genetic associations in asthma and allergy in Canadian families
Principal investigator: Peter Paré
Besides the potential that new therapies will be developed based on knowledge of the genes involved in asthma and allergic disease,it is likely that genetic analyses will predict who will respond best to specific therapies and who is most likely to develop an adverse response.
Projects: Neuroendocrine Regulation of Allergic Inflammation: Translational Studies; Biomarkers of a Sympathetic Anti-inflammatory Pathway, Neuro-regulation of Sympathetic Anti-inflammatory Activity
Principal investigator: Dean Befus
Researchers are beginning to understand the biology of a pathway involved in human allergy responses and inflammation, and are on the cusp of human clinical trials for novel medications that offer hope to patients around the world who suffer from allergic diseases…